Artelo Biosciences Reports First Quarter 2022 Financial Results And Provides Business Update [TheStreet.com]
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: TheStreet.com
$23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and Operations Into Second Half of 2023 Results of Phase 1b CAReS Trial Anticipated in Q3 2022 SOLANA BEACH, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the three months ending March 31, 2022. "We remain highly encouraged by the clinical data to date and we have yet to reach a maximum tolerated dose in our Phase 1b portion of the Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 for the treatment of cancer-related anorexia," stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. Mr. Gorgas continued, "We are also excited by new pre-clinical evidence of ART27.13 protecting from muscle wasting (cachexia), which is often associated w
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateGlobeNewswire
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation ChallengeGlobeNewswire
- Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th Accesswire
ARTL
Sec Filings
- 3/25/24 - Form 10-K
- 3/4/24 - Form 8-K
- 3/1/24 - Form 4
- ARTL's page on the SEC website